UBS Group AG Sells 297,317 Shares of Replimune Group, Inc. $REPL

UBS Group AG reduced its position in shares of Replimune Group, Inc. (NASDAQ:REPL) by 33.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 604,313 shares of the company’s stock after selling 297,317 shares during the quarter. UBS Group AG’s holdings in Replimune Group were worth $5,874,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of REPL. Russell Investments Group Ltd. boosted its holdings in Replimune Group by 3,638.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock valued at $33,000 after purchasing an additional 7,569 shares during the period. CWM LLC lifted its position in Replimune Group by 248.6% during the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after purchasing an additional 2,886 shares during the period. BNP Paribas Financial Markets grew its stake in Replimune Group by 99.8% during the third quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock worth $58,000 after buying an additional 6,873 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Replimune Group during the 2nd quarter worth approximately $69,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Replimune Group during the 3rd quarter worth approximately $81,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on REPL. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of Replimune Group in a report on Monday, April 13th. Cantor Fitzgerald lowered shares of Replimune Group from an “overweight” rating to a “hold” rating in a report on Monday, April 13th. Jefferies Financial Group restated a “hold” rating and set a $2.00 price objective (down from $13.00) on shares of Replimune Group in a research report on Monday, April 13th. Leerink Partners reiterated a “market perform” rating and issued a $2.00 target price (down from $11.00) on shares of Replimune Group in a report on Monday, April 13th. Finally, HC Wainwright restated a “sell” rating on shares of Replimune Group in a report on Monday, April 13th. Six analysts have rated the stock with a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, Replimune Group presently has a consensus rating of “Reduce” and a consensus price target of $4.75.

Insider Buying and Selling

In other Replimune Group news, insider Christopher Sarchi sold 6,500 shares of the company’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $8.01, for a total transaction of $52,065.00. Following the transaction, the insider owned 151,588 shares in the company, valued at approximately $1,214,219.88. This represents a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.20% of the company’s stock.

Replimune Group Stock Up 9.8%

REPL stock opened at $5.16 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60. Replimune Group, Inc. has a fifty-two week low of $1.50 and a fifty-two week high of $13.24. The stock’s 50 day simple moving average is $5.16 and its 200 day simple moving average is $7.42. The company has a market cap of $426.06 million, a P/E ratio of -1.50 and a beta of 0.12.

Replimune Group Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.